Premium
Primary hypothyroidism as a consequence of 131 ‐I‐metaiodobenzylguanidine treatment for children with neuroblastoma
Author(s) -
Picco Paolo,
Garaventa Alberto,
Claudiani Franco,
Gattorno Marco,
De Bernardi Bruno,
Borrone Carla
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19951101)76:9<1662::aid-cncr2820760924>3.0.co;2-v
Subject(s) - medicine , neuroblastoma , thyroid , thyroid function , thyroid function tests , pediatrics , genetics , biology , cell culture
Background . 131‐I‐metaiodobenzylguanidine is a radioiodinated compound selectively concentrated by cells of neuroectodermal origin, including neuroblastoma cells, for this reason it may represent a promising treatment modality for neuroblastoma in childhood. Although a potential side effect of 131‐I‐MIBG administration is thyroid dysfunction, relatively few data are reported about this issue. Methods . A series of 14 long term surviving patients with neuroblastoma who had been treated with 131‐I‐MIBG courses ranging from 2.5 to 5.5 gigabecquerels after surgical and conventional pharmacologic therapy is reported. Results . Twelve patients developed primary hypothyroidism that was clinically overt in 8 patients and compensated in 4 patients within 6–12 months of completion of 131‐I‐MIBG administration. Only in two patients was thyroid function spared. Significant correlations between the cumulative dose of 131‐I‐MIBG and the degree of thyroid failure were not found. Conclusions . Primary hypothyroidism appears to be a common side effect in children with neuroblastoma treated with 131‐I‐MIBG. This finding suggests that methods to preserve thyroid function other than oral administration of iodide should be sought. Cancer 1995; 76:1662–4.